🇺🇸 FDA
Patent

US 10646575

Heterocyclic degronimers for target protein degradation

granted A61KA61K31/4035A61K31/438

Quick answer

US patent 10646575 (Heterocyclic degronimers for target protein degradation) held by C4 THERAPEUTICS, INC. expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
C4 THERAPEUTICS, INC.
Grant date
Tue May 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
28
CPC classes
A61K, A61K31/4035, A61K31/438, A61K31/439, A61K31/454